Current approved therapeutic strategies for IPF and LC treatment

Proceedings of the ISCT scientific signature series symposium, “Advances in cell and gene therapies for lung diseases and critical illnesses” - Cytotherapy

Up-regulated SPP1 increases the risk from IPF to lung cancer via activating the pro-tumor macrophages - Computational and Structural Biotechnology Journal

MARKERS FOR MATURE BETA-CELLS AND METHODS OF USING THE SAME. Патент № US 20140329704 МПК C12Q1/68

PDF) Molecular Mechanisms and Cellular Contribution from Lung

Demographic data of the two dead patients during our study

A Review of the Treatment and Management of Idiopathic Pulmonary Fibrosis

PureTech Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022

Roberto TONELLI, Professor (Assistant), MD PhD

Stefania CERRI, Assistant Professor, MD, PhD

Luca TABBÍ, Medical Doctor, Doctor of Medicine

Valentina MASCIALE, PostDoc Position

Potential Therapeutic Targets of Resveratrol in the Prevention and Treatment of Pulmonary Fibrosis